Spacemarkers novel AI method identifies locations, interactions among genes in and around tumours

SpaceMarkers, a new machine learning software developed by researchers at the Johns Hopkins Convergence Institute and the Johns Hopkins Kimmel Cancer Center, can identify molecular interactions among distinct types of cells in and around a tumour.

New ‘pangenome’ offers more inclusive view of human genome

When it was launched in April 2003, the Human Genome Project helped revolutionize biomedical research by providing scientists a reference map that allowed them to analyze DNA sequences for genetic clues to the origins of a host of diseases.

Exothera partners with Quantoom Biosciences, launches new business unit for development and production of RNA

Exothera partners with Quantoom Biosciences, launches new business unit for development and production of RNA

Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in […]

biosynth logo

Biosynth strengthens peptide business with acquisition of Cambridge Research Biochemicals

Biosynth, a supplier of critical raw materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a leading independent producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors.

Bruker acquires ZONTAL to advance the digital lab transformation

Bruker acquires ZONTAL to advance the digital lab transformation

Bruker Corporation has acquired ZONTAL, an innovative platform provider for the digital transformation of the analytical laboratory, and for integrated biopharma technical data solutions. This acquisition further strengthens Bruker BioSpin’s Integrated Data Solutions (IDS) software division, which includes Mestrelab Research (www.mestrelab.com), Arxspan (www.arxspan.com) and Optimal (www.optimal-ltd.co.uk).

Scherm­afbeelding 2023 06 01 om 09.35.50

Oxford Nanopore, bioMérieux partner to develop infectious disease diagnostics

Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux, a world leader in the field of in vitro diagnostics, are teaming up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

Maxion Therapeutics awarded £2M Innovate UK funding to develop ion channel antibodies to treat autoimmune diseases

Maxion Therapeutics awarded £2M Innovate UK funding to develop ion channel antibodies to treat autoimmune diseases

Biotechnology company Maxion Therapeutics has been awarded a £2 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&D funding competition. The funds will support the use of Maxion’s proprietary KnotBody platform www.maxiontherapeutics.com/#technology to develop antibodies to treat autoimmune diseases (AID) with high unmet clinical need.

thermo fisher

Thermo Fisher Scientific, Pfizer collaborate to expand accesss to next-generation sequencing-based cancer testing in more than 30 countries

Pfizer and Thermo Fisher Scientific have agreed to collaborate to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can […]

Ken Hitchner

Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors. The announcement follows a series of appointments to the Company’s senior leadership team, as part of its ambitious global growth strategy.

Xyall and HALO AP

Xyall and Indica Labs forge global collaboration to transform precision oncology workflows

Xyall and Indica Labs have entered into a global strategic partnership designed to bridge the gap between histology and molecular pathology. It unites Xyall’s unique automated tissue dissection solutions with Indica Labs’ AI-powered, diagnostic digital pathology platform.